Regeneron and Sanofi declare plans to make Praluent more accessible for patients at high risk
For payers willing to reduce access barriers for high-risk patients, companies will offer net price within a cost-effective range, leveraging a new ICER analysis.
In order to help ensure more affordable and timely access to patients whose medical needs are unmet , Regeneron Pharmaceuticals and Sanofi will offer payers that agree to lessen burdensome access barriers for High-risk patients a further reduced net price for Praluent (alirocumab) Injection, in alignment with a new value assessment for high-risk patients from the Institute for Clinical and Economic Review.
The companies will take a precision medicine approach to address the burden of cardiovascular disease (CV), focusing efforts on high-risk patients most vulnerable to future CV events, such as those who have suffered a previous coronary event and are unable to reduce their LDL cholesterol (LDL-C) below 100 mg/dL despite maximally-tolerated statin therapy.
ICER’s established “in confidence” procedures, Regeneron and Sanofi provided early access to data from the ODYSSEY OUTCOMES trial to enable a revised assessment of alirocumab value incorporating the ODYSSEY OUTCOMES results. ICER is an independent organization that objectively evaluates the value of prescription drugs and other health care innovations.
Leonard S. Schleifer, MD, PhD, President and Chief Executive Officer of Regeneron said “We believe a new paradigm is needed in how all members of the healthcare community collaborate to ensure that patients are able to affordably access medical treatments they need. We commit to working with all health plans that agree to remove access barriers for high-risk patients to offer a more cost-effective net price for Praluent. We hope that our unprecedented approach to collaborating with payers and other stakeholders demonstrates that it is possible to bring major innovation to patients at a price that aligns with the value delivered.”
Praluent inhibits the binding of PCSK9 (proprotein convertase subtilisin/kexin type 9) to the LDL receptor and thereby increases the number of available LDL receptors on the surface of liver cells, which lowers LDL-C levels in the blood. The use of Praluent to reduce the risk of major adverse CV events is investigational and has not been evaluated by any regulatory agency.